Incyte (INCY) Set to Announce Earnings on Tuesday

Incyte (NASDAQ:INCY) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, July 30th. Analysts expect the company to announce earnings of $0.95 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.31). Incyte had a return on equity of 12.83% and a net margin of 19.78%. The company had revenue of $880.89 million for the quarter, compared to analyst estimates of $935.85 million. On average, analysts expect Incyte to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Incyte Stock Up 0.1 %

Shares of NASDAQ:INCY opened at $68.61 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.47 and a quick ratio of 3.43. The stock has a market cap of $15.41 billion, a price-to-earnings ratio of 20.79, a P/E/G ratio of 1.44 and a beta of 0.73. The company has a 50 day moving average of $61.03 and a 200-day moving average of $58.64. Incyte has a one year low of $50.27 and a one year high of $70.36.

Analyst Ratings Changes

A number of analysts recently commented on INCY shares. Oppenheimer lowered their price objective on shares of Incyte from $84.00 to $81.00 and set an “outperform” rating for the company in a research report on Friday. StockNews.com downgraded Incyte from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. BMO Capital Markets reaffirmed an “underperform” rating and set a $48.00 price target (down previously from $52.00) on shares of Incyte in a research report on Tuesday, July 2nd. Truist Financial reiterated a “buy” rating and issued a $83.00 price objective (down from $84.00) on shares of Incyte in a research report on Wednesday, May 1st. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a report on Tuesday, June 18th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, Incyte has a consensus rating of “Hold” and an average target price of $73.25.

Insider Transactions at Incyte

In other news, EVP Barry P. Flannelly sold 19,164 shares of Incyte stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $60.00, for a total value of $1,149,840.00. Following the transaction, the executive vice president now owns 66,377 shares in the company, valued at approximately $3,982,620. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Barry P. Flannelly sold 8,148 shares of the company’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $60.00, for a total value of $488,880.00. Following the completion of the transaction, the executive vice president now owns 50,534 shares of the company’s stock, valued at $3,032,040. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Barry P. Flannelly sold 19,164 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $60.00, for a total transaction of $1,149,840.00. Following the completion of the transaction, the executive vice president now owns 66,377 shares of the company’s stock, valued at $3,982,620. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,711 shares of company stock valued at $1,786,941. Company insiders own 17.50% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.